142253-50-7

Basic information

• Product Name: N-BOC-(2S)-PYRR(2-CHCN)
• Synonyms: N-BOC-(2S)-PYRR(2-CHCN);(S)-TERT-BUTYL 2-(CYANOMETHYL)PYRROLIDINE-1-CARBOXYLATE;1-Pyrrolidinecarboxylic acid, 2-(cyanoMethyl)-, 1,1-diMethylethyl ester, (2S)-;(S)-1-Boc-2-(cyanomethyl)pyrrolidine
• CAS NO: 142253-50-7
• Molecular Formula: C11H18N2O2
• Molecular Weight: 210.27
• Mol File: 142253-50-7.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 327.375 °C at 760 mmHg
• Flash Point: 151.791 °C
• Appearance: /
• Density: 1.062 g/cm³
• Vapor Pressure: 0.000203mmHg at 25°C
• Refractive Index: 1.478
• Storage Temp.: 2-8°C
• PKA: -2.57±0.40(Predicted)
• CAS DataBase Reference: N-BOC-(2S)-PYRR(2-CHCN)(CAS DataBase Reference)
• NIST Chemistry Reference: N-BOC-(2S)-PYRR(2-CHCN)(142253-50-7)
• EPA Substance Registry System: N-BOC-(2S)-PYRR(2-CHCN)(142253-50-7)

Safety Data

• Hazardous Substances Data: 142253-50-7(Hazardous Substances Data)

Usage

General Description

N-BOC-(2S)-PYRR(2-CHCN) is a chemical compound with a molecular formula of C16H21NO2. It is a derivative of N-BOC-2-pyrrolidinecarbonitrile and is primarily used in organic synthesis and pharmaceutical research. The compound contains a Boc (tert-butyloxycarbonyl) protecting group and a 2-pyrrolidinecarbonitrile moiety, making it a useful building block for the synthesis of various organic molecules. Its specific stereochemistry as a (2S)-pyrrolidine derivative allows it to be used in the synthesis of chiral compounds, particularly in the pharmaceutical industry where the stereospecificity of molecules is crucial for their biological activity.

InChI:InChI=1/C11H18N2O2/c1-11(2,3)15-10(14)13-8-4-5-9(13)6-7-12/h9H,4-6,8H2,1-3H3

Upstream product

• 86661-32-7 (S)-tert-butyl 2-((tosyloxy)methyl)pyrrolidine-1-carboxylate 
• 147-85-3 L-proline 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 773837-37-9 sodium cyanide 
• 132482-09-8 tert-butyl (2S)-2-{[(methylsulfonyl)oxy]methyl}-pyrrolidine-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 23356-96-9 (S)-1-Pyrrolidin-2-yl-methanol 
• 84890-94-8 (S)-2-Isobutoxycarbonyloxycarbonyl-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 69610-40-8 N-(tert-butoxycarbonyl)-L-prolinol 
• 1004993-43-4 tert-butyl (2S)-2-[(phenylselenonyl)methyl]pyrrolidine-1-carboxylate 
• 151-50-8 potassium cyanide 
• 143-33-9 sodium cyanide 

Downstream Products

• 1309563-52-7 (3aS,13aS)-N-[(2,4-difluorophenyl)methyl]-7,9-dioxo-8-[(phenylmethyl)oxy]-1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1',2':4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidine-10-carboxamide 
• 154887-98-6 (4S,6S)-conioidine A 
• 154887-98-6 (4S,6R)-conioidine A 
• 239483-09-1 tert-butyl (S)-2-(2-aminoethyl)pyrrolidine-1-carboxylate 

Relevant articles and documents

Synthesis and Stereochemical Assignment of Conioidine A: DNA- And HSA-Binding Studies of the Four Diastereomers

Conioidine A (1), isolated in 1993 with unknown relative and absolute configuration, was suggested to be a DNA-binding compound by an indirect technique. Four stereoisomers of conioidine A have been synthesized from d- and l-proline, and the natural product has been identified as possessing (4R,6R) absolute configuration. Binding of the conioidine diastereomers to calf thymus DNA (CT DNA) and human serum albumin (HSA) has been investigated by fluorescence spectroscopy and isothermal titration calorimetry (ITC). All stereoisomers display at least an order of magnitude weaker binding to DNA than the control compound netropsin; however, a strong association with HSA was observed for the (4R,6S) stereoisomer.

AUTOPHAGY-INHIBITING COMPOUNDS AND USES THEREOF

The present disclosure describes a compound for use in the treatment of cancer, infectious disease, and autoimmune disorders. The compounds herein can inhibit autophagy in an affected cell to promote cell death. Further, the compound can be used to overco

HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS

The present invention encompasses compounds of the formula (I) wherein the groups A, Cy, X1 and Y are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.